<DOC>
	<DOCNO>NCT02786641</DOCNO>
	<brief_summary>The investigator aim evaluate efficiency toxicity induction chemotherapy docetaxel , cisplatin xeloda nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Induction Chemotherapy TPX Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>All eligible patient receive intensity-modulated radiotherapy ( IMRT ) total dose 68 Gy high 33 fraction primary tumor . Nomogram-predicted low risk patient ( Group A ) receive concurrent chemotherapy , nomogram-predicted high risk patient randomize receive concurrent chemotherapy ( Group B ) induction chemotherapy follow concurrent chemotherapy ( Group C ) . Induction chemotherapy consist docetaxel 65 mg/m² , D1 , cisplatin 75 mg/m² , D1 Xeloda 2000mg/m² , D1-14 every 3 week 3 cycle . Concurrent chemotherapy consist cisplatin 100 mg/m² , D1 every 3 week 3 cycles.The primary endpoint failure-free survival ( FFS ) . Secondary end point include overall survival ( OS ) , locoregional relapse-free survival ( LRFS ) , distant metastasis-free survival ( DMFS ) incidence grade 3 high acute toxicity . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Newly histologically confirm nonkeratinizing ( WHO 1991 ) nasopharyngeal carcinoma . Tumor stag IIIIVb ( 2010 UICC/AJCC stag system ) . Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4×10E9/L , hemoglobin ≥ 110g/L platelet count ≥ 100×10E9/L . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) bilirubin ≤ 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min creatinine ≤ 1.5×ULN . Patients must give write informed consent . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous radiotherapy ( except nonmelanomatous skin cancer outside intend radiotherapy volume ) . Prior radiotherapy , chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance . Deficient dihydropyrimidine dehydrogenase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>concurrent chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>xeloda</keyword>
	<keyword>nomogram</keyword>
</DOC>